Bey Douglas LLC Raises Stock Holdings in Johnson & Johnson $JNJ

Bey Douglas LLC increased its position in Johnson & Johnson (NYSE:JNJ) by 5.4% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,043 shares of the company’s stock after purchasing an additional 104 shares during the period. Bey Douglas LLC’s holdings in Johnson & Johnson were worth $312,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in JNJ. Brighton Jones LLC boosted its holdings in Johnson & Johnson by 13.9% in the fourth quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock worth $7,502,000 after acquiring an additional 6,332 shares in the last quarter. Wealth Group Ltd. bought a new stake in Johnson & Johnson in the first quarter worth $218,000. GAMMA Investing LLC boosted its holdings in Johnson & Johnson by 48.0% in the first quarter. GAMMA Investing LLC now owns 43,508 shares of the company’s stock worth $7,215,000 after acquiring an additional 14,118 shares in the last quarter. Wealth Enhancement Advisory Services LLC boosted its holdings in Johnson & Johnson by 6.7% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 1,698,831 shares of the company’s stock worth $281,734,000 after acquiring an additional 107,009 shares in the last quarter. Finally, Blodgett Wealth Advisors LLC boosted its holdings in Johnson & Johnson by 2.2% in the first quarter. Blodgett Wealth Advisors LLC now owns 4,894 shares of the company’s stock worth $812,000 after acquiring an additional 106 shares in the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Stock Up 0.1%

JNJ stock opened at $190.88 on Tuesday. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $192.10. The business’s 50-day moving average is $178.88 and its two-hundred day moving average is $163.97. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01. The company has a market cap of $459.71 billion, a price-to-earnings ratio of 20.42, a P/E/G ratio of 2.40 and a beta of 0.40.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The company had revenue of $24.02 billion for the quarter. As a group, analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th were issued a $1.30 dividend. The ex-dividend date of this dividend was Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a yield of 2.7%. Johnson & Johnson’s dividend payout ratio is currently 55.61%.

Analyst Ratings Changes

JNJ has been the topic of several analyst reports. Wells Fargo & Company set a $212.00 target price on Johnson & Johnson and gave the stock an “overweight” rating in a report on Friday, October 3rd. The Goldman Sachs Group boosted their target price on Johnson & Johnson from $186.00 to $212.00 and gave the stock a “buy” rating in a report on Thursday, October 9th. Bank of America upped their price target on Johnson & Johnson from $175.00 to $198.00 and gave the company a “neutral” rating in a report on Friday, October 3rd. Wall Street Zen raised Johnson & Johnson from a “hold” rating to a “buy” rating in a report on Saturday, September 13th. Finally, Sanford C. Bernstein upped their price target on Johnson & Johnson from $172.00 to $193.00 and gave the company a “market perform” rating in a report on Monday, October 6th. Two analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and eight have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Johnson & Johnson has a consensus rating of “Moderate Buy” and an average target price of $192.94.

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the transaction, the executive vice president owned 178,013 shares of the company’s stock, valued at approximately $31,652,491.53. This represents a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.